Intra-Cellular Therapies

This Thanksgiving, the team at Intra-Cellular Therapies wants to take a moment to express our heartfelt gratitude and thanks to our dedicated employees for their hard work and commitment to excellence. ? We also extend our appreciation to the patients, families, and healthcare professionals who inspire us with their strength and resilience and motivate us to develop and deliver innovative treatments for those living with neuropsychiatric, neurologic, and other disorders. ? Happy Thanksgiving! #Thanksgiving #IntraCellularTherapies

We are proud that Intra-Cellular Therapies has been recognized on the Deloitte Technology Fast 500?, a ranking of the fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies in North America. ? Being a part of the Fast 500 is a tribute to the dedication and passion of our employees, partners, and everyone who shares in our mission to enhance the lives of individuals affected by serious mental health conditions. ? A heartfelt thank you to our incredible team and supporters for your commitment and belief in our vision. Together, we are making a real difference! Learn more: https://lnkd.in/eAFbRpi6 #DeloitteFast500 #IntraCellularTherapies

This Veterans Day, Intra-Cellular Therapies honors the brave women and men who have served in the U.S. Armed Forces. Their dedication and sacrifice have paved the way for the freedoms we enjoy every day. We express our sincere gratitude and thank you for your service! ? #VeteransDay #MentalHealthAwareness #IntraCellularTherapies

This National Nurse Practitioner Week, Intra-Cellular Therapies would like to extend our heartfelt appreciation and gratitude to the dedicated nurse practitioners across the U.S. who play a vital role in supporting individuals living with mental health conditions. ? Their expertise and compassionate approach to patient care, education, and advocacy is invaluable. Thank you for your unwavering dedication and for being a critical part of the mental health community.?

BREAKING NEWS: Today we are pleased to announce positive topline results from our Phase 3 trial, Study 304, evaluating the efficacy and safety of our product for the prevention of relapse in adult patients with schizophrenia. Learn more:?https://lnkd.in/em_Z9man

Intra-Cellular Therapies is pleased to support the NEI Congress as they celebrate their 20th anniversary in Colorado Springs this week. Come visit us at Booth #503 and attend ITCI’s educational program on Nov. 7, at 7:00 a.m. MT. See you there!?

Every November, we acknowledge the hard work and dedication that family caregivers provide. They are often family members and friends who step up during challenging times to offer both practical assistance and emotional support that fosters resilience and hope. Their dedication makes a significant difference in the lives of those they care for—yet often, their sacrifices go unnoticed. This National Family Caregivers Month, let’s recognize their contributions and raise awareness about the resources available for those taking on this important role. https://lnkd.in/ek9uEVVR

Happy Diwali! May the Festival of Lights inspire us to reach new heights and create a brighter future.?Employees who celebrate Diwali had the opportunity to share their traditions with colleagues yesterday at a luncheon held in our NJ office.????

Come visit Intra-Cellular Therapies this week at Psych Congress in Boston at Booth #1115 and attend our “Lighting Round Learning” presentation with Dr. Roger McIntyre and Erin Crown, PA-C, on Oct. 31 at 7:30 a.m. ET. The presentation, “Clinical Perspectives on Bipolar I and Bipolar II Depression, and a Treatment Option Approved for Both,” will be in Room 205 AB.

Attending the Annual Medscape Psychopharmacology Update in Cincinnati this week? Intra-Cellular Therapies invites you to attend the education presentation “Exploring Diagnostic Specifiers in Bipolar Disorder and a Treatment Option for BOTH Bipolar I and Bipolar II Depression in Adults” presented by Dr. Vladimir Maletic on Saturday, Oct. 26 at 3:20 p.m. CT.?